Vimarsana
Biggest News Aggregation in the World

Page 13 - Thomas Pedersen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thomas Pedersen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thomas Pedersen Today - Breaking & Trending Today

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma - Vimarsana News

Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allarity Therapeutics Announces Positive Data from Preclinical Study of Dovitinib in Osteosarcoma Allarity Therapeutics A/SMarch 9, 2021 GMT - Treatment of animal osteosarcoma models with dovitinib increased the median survival time by 50 % as compared to control animals. Press release   Hørsholm, Denmark (9 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced positive data from its preclinical assessment of dovitinib’s antitumor activity in osteosar...

Source: apnews.com
Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer - Vimarsana News

Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer

Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer Allarity Therapeutics A/S Press release       Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2 clinical trial of IXEMPRA ® (ixabepilone) for the treatment of metastatic breast cancer. The U.S. Food and Drug Administration (FDA) approved IXEMPRA ®, a microtubulin inhibitor, in 2007 for the treatment of metastatic breast cancer. Allarity h...

What's Happening in Ilion With Mayor and Fire Dept.? - Vimarsana News

What's Happening in Ilion With Mayor and Fire Dept.?

Things are heating up at the Ilion Fire Department and this issue has nothing to do with a blaze. Since the end of last year, there have been heated relations between the fire department leadership, versus Ilion Mayor Brian Lamica, and Deputy Mayor Chuck Lester, according to residents close to the conflict. Now, three members of the department have been disciplined including the fire chief, Thomas Pedersen, who has now been removed from his position. According to reports, Pedersen has been demoted in the fire department and retains his position as village codes officer. Two other members ...

Autonomy Is A Journey: Wärtsilä Voyage Helps Define And - Vimarsana News

Autonomy Is A Journey: Wärtsilä Voyage Helps Define And

Image: Wärtsilä Voyage One the key efforts is to first make sure that there is a proper integration between our system and the propulsion system on the vessel. When that is done, we start tuning the system and doing some dry runs via simulation (simulation on the specific routes the vessel normally sails). Thomas Pedersen, Director, Automation & Dynamic Positioning, Wärtsilä Voyage. Photo courtesy Wärtsilä Voyage MV American Courage, a 194 metres Great Lakes self-unloading bulk freighter with a cargo carrying capaci...

Allarity Therapeutics A/S: Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus - Vimarsana News

Allarity Therapeutics A/S: Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential therapy for new highly infectious Strain B.1.1.7 of Coronavirus

(2) Press Release Hørsholm, Denmark (26 January 2021) - Allarity Therapeutics A/S ("Allarity" or the "Company") today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU). The virus variant was labelled "Variant of Concern 202012/01" by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to ...